Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAART duration in primary HIV-1 infection
NL-OMON20081Active, not recruiting
- Start
- May 2003
- Countries
- 1
01
Overview
Randomised, triple-blind trial in Human immunodeficiency virus infection type 1 and Seroconversion Syndrome (3 arms). Primary endpoints: Viral set-point and viral rebound kinetics and Time off therapy after discontinuation. Started May 2003; status: active, not recruiting.
02
Conditions
Human immunodeficiency virus infection type 1Seroconversion Syndrome
Beyond the preview
Go deeper on NL-OMON20081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20081.